We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 179

Generics v Lundbeck - distinguishing the sufficiency requirements for product and process claims
  • Gowling WLG
  • United Kingdom
  • May 19 2008

In Generics v Lundbeck, the Court of Appeal provided important guidance on the judgment of the House of Lords in Biogen v Medeva regarding the scope of protection to which an inventor is entitled and the enabling disclosure the specification must provide to support the claims in the patent


Immunex Corporation v. Canada (Minister of Health)
  • Gowling WLG
  • Canada
  • February 9 2009

The Court upheld the Minister's refusal to list the patent on the Patent Register on the basis that it did not contain a claim for the dosage form


Merck triumphs as new and inventive dosing regimen held patentable
  • Gowling WLG
  • United Kingdom
  • May 29 2008

Actavis sued to revoke Merck's patent with a second medical use claim (in the so-called 'Swiss form') for the use of finasteride in the preparation for a drug to treat androgenic alopecia with a lower dosage than disclosed in the prior art


Sanofi v ratiopharm, PMNOC Regulations decision irbesartan, March 5, 2010
  • Gowling WLG
  • Canada
  • May 21 2010

Sanofi sought an order prohibiting the granting of a NOC to ratiopharm


Pfizer v Ranbaxy; 55.2 proceeding; October 5, 2007 - atorvastatin
  • Gowling WLG
  • Canada
  • October 25 2007

The trial judge granted prohibition in respect of one patent claiming a novel crystalline form of atorvastatin (the "crystalline form patent") and denied prohibition in respect of another patent claiming a novel process for making atorvastatin (the "process patent"


Data protection: defining innovative drug in Canada
  • Gowling WLG
  • Canada
  • April 22 2013

Canada amended its Data Protection Regulations in 2006 to provide protection for innovative drugs in a second attempt to implement Canada's 1994


Federal court affirms standing for innovative drug manufacturer
  • Gowling WLG
  • Canada
  • July 23 2014

What rights do innovative drug manufacturers have in situations where generics challenge certain Health Canada decisions but do not name the


Recent cases
  • Gowling WLG
  • Canada
  • August 1 2008

The Court of Appeal overturned the motions judge's decision striking the notice of appearance


Apotex v. AB Hassle; appeal motion to dismiss impeachment proceeding; June 27, 2007; omeprazole
  • Gowling WLG
  • Canada
  • July 13 2007

The two companies litigated this patent in proceedings under the PMNOC Regulations


Pfizer v. Ranbaxy; appeal of motion to dismiss 55.2 proceeding, S. 6(5); June 18, 2007 Atorvastatin
  • Gowling WLG
  • Canada
  • July 13 2007

The generic company brought a motion to dismiss the proceeding as an abuse of process